TABLE 1

Patient Characteristics

							HER2 FISH			Range of SUV_mean of lesions
Group	Patient no.	Age (y)	IA (MBq)	Tumor type	ER/PR	HER2 IHC	Positivity	Ratio	Copies/cell	Primary tumor	Local ADP	Distant M+ (type)
0.01 mg	1	43	77	IDC	+/+	2+	+	2.2	6.2	ISR^*	A	A
	2	60	66	IDC	+/+	3+	+	>2	Macroclusters	CR	A	3.1 (bone)
	3	68	53	IDC	+/+	3+	+	12.2	20.0	3.2	A	A
	4	53	76	IDC	+/+	2+	−	1.3	3.7	2.2	A	A
	5	74	84	IDC	+/+	2+	−	1.3	3.8	2.3	A	A
	6	34	83	IMeC	+/−	3+	+	2.8	8.0	0.9	A	A
	7	34	80	IDC	+/+	2+	−	1.0	1.4	2.0	A	A
0.1 mg	8	67	92	IDC	+/+	2+	−	1.4	3.4	5.0	3.2–4.3	1.0–5.6 (bone)
	9	57	111	IDC	+/+	3+	+	1.3	6.1	2.3	A	A
	10	61	100	IDC	+/−	3+	+	9.4	15.0	SR	SR	4.1–5.7 (bone)
	11	65	90	IDC	+/+	3+	+	2.3	5.1	2.9	6.3	A
	12	46	82	IDC	+/+	3+	+	8.1	15.6	1.4	A	A
	13	32	153	IDC	−/−	2+	+	9.4	17.4	3.2	1.7	A
	14	53	103	IDC	−/−	3+	+	4.7	9.2	11.8	13.0	A
	15	78	148	IDC	+/+	2+	−	1.0	2.1	4.9	A	A
1.0 mg	16	76	96	ILC	+/+	2+	−	1.0	1.7	SR	SR	2.2–3.9 (bone)
	17	74	138	IDC	−/−	2+	−	1.2	4.3	1.8	A	A
	18	62	167	IDC	+/−	2+	+	2.6	4.5	SR	SR	3.5–6.0 (ADP mediastinum)
	19	62	174	IMiC	+/+	3+	+	2.8	8.0	4.4	5.1–5.9	3.6–3.9 (bone)
	20	48	170	IDC	+/+	3+	+	7.8	15.6	0.7^†	A	4.7–5.4 (bone)^†

↵* Patient was scanned after incomplete surgical removal but additional surgical resection could not demonstrate remaining tumor cells.
↵† After 4 cycles of epirubicin cyclophosphamide.
FISH = fluorescence in situ hybridization; IA = injected activity; ER = estrogen receptor; PR = progesterone receptor; IHC = immunohistochemical assessment; ADP = adenopathy; IDC = invasive ductal carcinoma; ISR = incomplete surgical removal; A = absent; CR = complete response on CT; IMeC = invasive medullary carcinoma; SR = surgically removed; ILC = invasive lobular carcinoma; IMiC = invasive mixed carcinoma.